Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Atezolizumab can induce sustained responses in metastatic urothelial carcinoma. We report the results of IMvigor130, a phase 3 trial that compared atezolizumab with or without platinum-based chemotherapy versus placebo plus platinum-based chemotherapy in first-line metastatic urothelial carcinoma.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet

Title: Lancet (London, England)

Publisher: Elsevier BV

ISSN (Electronic): 1474-547X

ISSN (Print): 0140-6736

Publication date (Electronic): May 16 2020

Volume: 395

Issue: 10236

Affiliations

[1 ] Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY, USA. Electronic address: matthew.galsky@mssm.edu.

[2 ] Hospital General Universitario Gregorio Marañón, Madrid, Spain.

[3 ] National and Kapodistrian University of Athens, Athens, Greece.

[4 ] Eastern Health, Monash University, Melbourne, VIC, Australia.

[5 ] Charité University Hospital, Berlin, Germany; Department of Urology, Medical University, Vienna, Austria.

[6 ] Keio University School of Medicine, Tokyo, Japan.

[7 ] Catalan Institute of Oncology, IDIBELL, University of Barcelona, Barcelona, Spain.

[8 ] Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS, Meldola, Italy.

[9 ] Institute of Oncology Ljubljana, Ljubljana, Slovenia.

[10 ] Kanazawa University Hospital, Kanazawa, Japan.

[11 ] Istituti Ospitalieri Cremona, Cremona, Italy.

[12 ] Istanbul Medeniyet University, Goztepe Research Hospital, Istanbul, Turkey.

[13 ] Istanbul University-Cerrahpaşa, Cerrahpaşa School of Medicine, Istanbul, Turkey.

[14 ] Norton Cancer Institute, Louisville, KY, USA.

[15 ] Sungkyunkwan University Samsung Medical Center, Seoul, Korea.

[16 ] P Herzen Oncology Research Institute, Moscow, Russia.

[17 ] Beneficencia Portuguesa de São Paulo, São Paulo, Brazil.

[18 ] Taichung Veterans General Hospital, HungKuang University, Taichung, Taiwan.

[19 ] Fudan University Shanghai Cancer Center, Shanghai, China.

[20 ] Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA.

[21 ] Roche, Welwyn Garden City, UK.

[22 ] Genentech, San Francisco, CA, USA.

[23 ] F Hoffmann-La Roche, Basel, Switzerland.

[24 ] MD Anderson Cancer Center Madrid, Madrid, Spain.

Article

Publisher Item ID: S0140-6736(20)30230-0

DOI: 10.1016/S0140-6736(20)30230-0

PubMed ID: 32416780

SO-VID: 171b7a0b-873b-42dd-be5b-74c69f9be4a8

History

Data availability:

Comments

Comment on this article

scite_

Smart Citations

Citing PublicationsSupportingMentioningContrasting

View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.